The global prefilled syringes market size is estimated to grow from USD 3.02 billion in 2024 to USD 4.97 billion by 2035, representing a CAGR of 4.6% during the forecast period till 2035.
The different driving factors for the prefilled syringes market include the growing prevalence of chronic diseases (requiring long-term treatments), rising development of biologics (requiring precise dosing) and increasing trend towards self-administration. Our estimates suggest that, in 2023, the maximum revenue generated in this domain is likely to be driven by specialty syringes; this trend is unlikely to change in the foreseen future as well.
Presently, the majority share (50%) of the sales revenues is generated by therapeutic prefilled syringes storing proteins, followed by therapeutic prefilled syringes storing antibodies (31%). It is worth mentioning that, in 2035, blood disorders are likely to dominate the prefilled syringe market.
In terms of type of barrel material, the market is likely to be dominated by glass prefilled syringes. Furthermore, over 70% of the market share is captured by single chamber prefilled syringes; however, the dual chamber prefilled syringes market is anticipated to grow at a relatively faster pace.
In 2023, maximum revenue generated in prefilled syringe domain is likely to be driven by the disposable prefilled syringes, followed by reusable prefilled syringes. In terms of type of syringe, more than 65% share of the market is expected to be captured by safety syringes and is likely to grow at a CAGR of around 7%. It is important to highlight that currently, North America and Europe are likely to capture more than 70% of the overall share in prefilled syringe market.
During our research, we came across various recent developments that were undertaken by prefilled syringe manufacturers. Expansions emerged as the most prominent type of initiative undertaken by stakeholders engaged in this domain; most of the expansion initiatives undertaken by prefilled syringe manufacturers within this domain were facility expansions and capacity expansions.
It is worth noting that various innovative prefilled syringes have been launched, over the years; manufacturers across the world are focusing on incorporating latest technological innovations in their products, improving quality and offering a competitive edge over other stakeholders. Notably, around 40% of the partnerships related to prefilled syringes were reported in 2021; majority of the partnerships in this domain were technology integration agreements.
In pursuit of building a competitive edge, stakeholders are actively upgrading their existing capabilities to enhance their product portfolios and comply with the evolving industry benchmarks.
In order to determine the relative competitiveness of prefilled syringes, we focused on several relevant parameters, such as manufacturer strength (in terms of experience and company size), product portfolio strength (in terms of current status of development, number of chambers and volume of syringe available) and type of needle system (luer lock, luer cone and staked needle).
In this peer group, SCHOTT TopPac (manufactured by SCHOTT Pharma) emerged as the most competent prefilled syringe, in terms of product portfolio strength, followed by Gx RTF ClearJect Needle Syringe (manufactured by Gerresheimer), available in staked needle format is produced in the company’s facility located in Pfreimd, Germany.
In terms of manufacturer strength, Pfizer (very large US-based firm) emerged as the leading player in this domain, having an experience of close to 175 years; the Abboject Syringe manufactured by the firm is a ready-to-use, prefilled emergency syringe for needle-free or shrouded-needle access.
Increase in the intellectual capital- an evidence for progression in R&D activity for prefilled syringes and its components.
Over 1,300 patents related to prefilled syringes and its associated components have been filed / granted, indicating the heightened pace of innovation in this domain.
Majority of the patents were filed / granted in North America, followed by those filed / granted in Europe, WIPO, and Asia-Pacific and rest of the world. Despite the large number of patents that have been filed recently (and hence having a long remaining patent life), only 3% of the total patents filed in this domain have a significantly higher relative valuation. This is primarily because of the relatively low citations of the patents that have been filed recently, leading to low patent value.
To know more about the report, visit @
https://www.rootsanalysis.com/reports/prefilled-syringes-market/284.html
Thank you for reading our report. To know more about the customization feature, please get in touch with us, and our team will ensure the report is customized to meet your requirements.
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports we provide are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.
Contact Details
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/
